Breaking News

Catalent Ups Stake in Redwood Bioscience

SMARTag ADC Technology achieves key milestone

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions has increased its minority investment in Redwood Bioscience. The decision was based on data generated by the SMARTag ADC platform, a precision protein-chemical engineering platform and novel toxin-linker technology developed by Redwood to enable the generation of homogeneous antibody-drug conjugates (ADCs) engineered to enhance potency, safety and stability. Employing Redwood’s SMARTag ADC platform combined with Catalent’s GPEx cell line expression system, the companies...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters